| Title |
Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study
|
|---|---|
| Published in |
Clinical Rheumatology, April 2018
|
| DOI | 10.1007/s10067-018-4080-8 |
| Pubmed ID | |
| Authors |
Hani M. Khojah, Sameh Ahmed, Mahran S. Abdel-Rahman, Eman H. Elhakeim |
| Abstract |
Resveratrol (RSV), a naturally occurring polyphenol, has been found to have potent antioxidant, anti-inflammatory, and anticancer effects. Recently, RSV was reported as a new potential agent to suppress inflammation of collagen-induced arthritis in a mouse model. Nevertheless, the clinical benefits of RSV in the management of rheumatoid arthritis (RA) were not studied. This randomized controlled clinical trial aims to shed some light on the therapeutic benefits of RSV in the treatment of RA in patients with different stages of the disease activity. In this randomized controlled clinical trial, 100 RA patients (68 female, 32 male) were enrolled randomly and divided into two groups, each of 50 patients: an RSV-treated group that received a daily RSV capsule of 1 g with the conventional treatment for 3 months and a control group that just received the regular treatment. The clinical and biochemical markers of RA in both groups were assessed. It was found that the clinical markers (i.e., the 28-joint count for swelling and tenderness) and the disease activity score assessment for 28 joints were significantly lowered in the RSV-treated group. Moreover, serum levels of certain biochemical markers (i.e., C-reactive protein, erythrocyte sedimentation rate, undercarboxylated osteocalcin, matrix metalloproteinase-3, tumor necrosis factor alpha, and interleukin-6) were also significantly decreased in RSV-treated patients. The current study suggests the addition of RSV as an adjuvant to the conventional antirheumatic drugs. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Germany | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 126 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 126 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 15 | 12% |
| Other | 14 | 11% |
| Researcher | 11 | 9% |
| Student > Master | 11 | 9% |
| Student > Ph. D. Student | 10 | 8% |
| Other | 19 | 15% |
| Unknown | 46 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 23% |
| Nursing and Health Professions | 11 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 9% |
| Biochemistry, Genetics and Molecular Biology | 8 | 6% |
| Chemistry | 4 | 3% |
| Other | 12 | 10% |
| Unknown | 51 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 August 2022.
All research outputs
#1,028,595
of 23,172,045 outputs
Outputs from Clinical Rheumatology
#75
of 3,058 outputs
Outputs of similar age
#25,066
of 329,378 outputs
Outputs of similar age from Clinical Rheumatology
#3
of 68 outputs
Altmetric has tracked 23,172,045 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,058 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,378 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.